US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye: AroCell - Changes to the Case

Redeye significantly raises its Base Case for AroCell, given fundamental changes to the case following recent FDA filing in combination with close discussions with management. The company is transitioning to a more commercially oriented business with anticipated key activities in the coming 6-9 months. At a current market capitalization of roughly SEK 130m, we see great upside in the stock on all horizons. Read more and download the research update  Start following companies at Redeye to receive the latest equity

Redeye: AroCell - Funding secured, next step - FDA

We adjust our financial projections given a new view on pricing and market uptake for AroCell. In our update we slightly raise our Base Case to SEK 2.5 per share and discuss the capital raise, which we believe will fund operations until FDA approval in 2021. Read more and download the research update: http://bit.ly/2RRyNRh Start following companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye initiates coverage of AroCell

We initiate coverage of AroCell, a diagnostics company that focuses on the research, development and sales of an in vitro diagnostics product for cancer, called TK 210 ELISA, and the licensing of the technology behind this. After several years focusing on research and development, AroCell is now switching over to a commercial focus with itsTK 1 technology for cancer therapy response analysis. We see several potential catalysts in the short- and mid-term that are positive for the stock. Read more and download the research update: http://bit.ly/2Jevv6g Start following companies at

AroCell is approved for listing on the Nasdaq First North and publishes Corporate description

AroCell AB (publ) has been accepted for trading on Nasdaq First North. The last day of trading on AktieTorget is the 29 June 2016 and the first day of trading on Nasdaq First North is the 30 June 2016.AroCell will continue to be traded under the ticker symbol AROC with current ISIN code SE0003883990. Redeye AB will act as the company's Certified Adviser on First North. The company has established a corporate description approved by Nasdaq First North, which from today is available on the AroCells website, www.arocell.com 

AroCell applying for listing on the Nasdaq First North

The Board of Directors of AroCell AB (publ) have decided to apply for listing of the company shares to trading on the Nasdaq First North exchange, and thereby change market for share listing.The change of market listing is planned to take place at the turn of the month June/July 2016, and the first date for trading will be announced after approval from the Nasdaq First North exchange. “The assessment of the Board and Management is that Nasdaq First North is a market exchange that will provide a broader exposure of the company to more groups of investors and institutions. It will also

Christine Tadgell new board member in AroCell

Christine Tadgell has been elected as board member in AroCell AB (publ) at the Annual General Meeting on May 18, 2016Christine Tadgell received a Bachelor of Science degree at Concordia University, Montreal, Quebec, Canada. She is currently Vice-President for the inVentiv Health European Commercial Group situated in London, UK. She has a background within the area of biopharmaceuticals and international experience from Europe and North America, as well as extensive experience of commercial strategy within the pharmaceutical industry. -The competence within the board will be additionally

Report from the Annual General Meeting of AroCell

On May 18 2016, AroCell AB (publ) held its Annual General Meeting. The resolutions from the Meeting are summarised below. All resolutions were adopted with necessary majority4,420,294 (15.4 percent) of the total of 28,674,506 shares were represented at the meeting. The Meeting resolved to adopt the presented income statement and balance sheet. The Meeting also resolved to allocate the company’s loss in accordance with the Board of Directors’ proposal in the Annual Accounts. It was further resolved that no dividend would be paid for financial year 2015. The Meeting resolved to

Interim report, 1 January – 31 March 2016

· Net sales were TSEK 0 (0) · Loss after financial items was TSEK -2,842 (-2,402) · Earnings per share where SEK -0.10 (-0.10) · Cash flow from operating activities was TSEK -1,272 (-3,255) · Scale-up of production processes for TK 210 ELISA proceeds according to plan · The Ethical review board for Stockholm South General Hospital (Södersjukhuset) approved the start of a clinical study regarding follow-up of prostate cancer patients with TK 210 ELISA · The Ethical committee for the University Hospital of Helsinki approved the start of a clinical study regarding follow-up

Leading profile in biomarkers joins the AroCell management team

AroCell AB announces the addition of Martin Shaw as Business Development Manager to the management team. Martin Shaw has over 40 years’ experience in the development and introduction of novel biomarker assays, to the pharmaceutical, biotechnology and laboratory medicine industries.  Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in

New patent strengthens the AroCell patent portfolio

The European Patent Office has confirmed the grant of a patent to AroCell AB regarding an invention relating to exposed thymidine kinase 1 (TK1) derived peptides, ligands and methods employing these. “We are delighted to hear that the European Patent Office has granted us this patent regarding exposed proliferation related peptides”, states Jan Stålemark, AroCell CEO. “This latest patent provides us with an additional level of protection for our unique TK 210 ELISA test, as we continue to establish the clinical validation of our product”. For further information: Jan Stålemark, CEO

New clinical study with promising results for the TK 210 ELISA test from AroCell

This study published in the journal Tumor Biology, included 124 breast cancer patients with known TNM classification and known values of the well-established breast cancer biomarker CA 15-3. Additionally, 53 healthy individuals were also included in the study, where serum samples were analyzed with the AroCell TK 210 ELISA test, which measures TK1 protein levels. Results demonstrated that the TK 210 ELISA test showed significantly higher sensitivity compared to the TK1 activity test with serum samples from breast cancer patients, particularly with patients in early stages of disease. “We

Final call for trading with BTA

During the month of December 2015 AroCell AB (publ) conducted a preferential rights issue. The last day for trading with BTA will take place on January 12th 2016 and the stop day is January 14th 2016. BTA’s will be converted to shares January 18th 2016. After the preferential rights issue the share capital will be 2 867 450,60 SEK distributed on 28 674 506 shares. Redeye AB is the financial advisor for the preferential rights issue in collaboration with Corpura AB. Legal advisor is Fredersen Advokatbyrå AB. For more information:Jan Stålemark, CEOAroCell AB (publ)Tel: +46(0)

Nomination committee appointed for Annual General Meeting 2016

A decision was taken on June 3, 2015 at the Annual General Meeting for AroCell AB (publ) that a nomination committee should be appointed and should consist of three members, comprised of the three largest shareholders on September 30, 2015, and the Chairman of the Board. The nomination committee has been appointed accordingly, based on shareholdings on September 30, 2015: Bernhard Tribukait, representing his own shareholdingsArne Ferstad, representing his own and related shareholdingsStaffan Eriksson, representing his own and related shareholdingsErik Walldén, Chairman of the

Oversubscription of preferential rights issue

The preferential rights issue in AroCell AB (publ) was oversubscribed to 53.8 million Swedish kronor, including subscription rights. This corresponds to a subscription level of approximately 103 percent, of which 76 percent was with preferential rights. This will provide AroCell with approximately 52.2 million Swedish kronor before issue expenses and there will be no need to utilize the guarantee obligations that have been provided.AroCell CEO Jan Stålemark comments:It is with honor and satisfaction to receive this confidence from our shareholders. By conducting the plan that we have

Announces prospectus, teaser and application form

The Board of AroCell AB (publ) has prepared a prospectus for the purpose of the preferential rights issue, which was announced on November 6, 2015. The prospectus has today, November 17, 2015, been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) in accordance with the Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument). The prospectus, a teaser and the application form are available on AroCell’s website (www.arocell.com) and on AktieTorget’s website (www.aktietorget.se).Summary of rights issue

Progress for development of prostate treatment, results from STHLM3 presented today

Helena Wensman comments the new KI study                       We see the results from the large STHLM3 study as very positive news, not only as development is progressing and treatment may improve, but also because it provides positive effects for companies that work within this area, including AroCell. STHLM3 study is based on a very large number of genetic markers which are associated with risk for prostate cancer. These genetic markers are then combined with detailed patient information to make the test more reliable, to elevate safety in diagnosis of suspected prostate cancer.

Interim report, 1 January – 30 September 2015

Interim report, 1 January – 30 September 2015 · Net sales were TSEK 0 (0) · Loss after financial items was TSEK -5,857 (-3,610) · Earnings per share where SEK -0.25 (-0.19) · Cash flow from operating activities was TSEK -4,676 (-3,284) Reporting period, 1 July – 30 September 2015 · Net sales were TSEK 0 (0) · Loss after financial items was TSEK -1,811 (-1,064) · Cash flow from operating activities was TSEK -891 (-491) · TK 210 ELISA test successfully passes phase 1 review of production process · AroCell recognized by EU Commission and Horizon 2020 · CE-

Announces interim report three will be brought forward

The board of directors of AroCell AB (publ) has taken a decision to bring forward interim report three to November 10, 2015 (previously November 17, 2015) as a consideration to the planned preferential rights issue.For further information: Jan Stålemark, CEOAroCell AB (pub)Tel: +46-706696206info@arocell.comwww.arocell.com About AroCell AB (publ)AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which

Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK.

The Board of Directors of AroCell AB has resolved on November 5, 2015 after the closing of the stock exchange, with support of the decision taken at the Annual General Meeting, a preferential rights issue of maximum 5 213 546 shares. Full subscription of the preferential rights issue will provide AroCell with a maximum of MSEK 52.2 before issue expenses. The company has received subscription undertakings from members of the board of directors, management and the company’s largest shareholders, and signed agreements accordingly to fully guarantee the preferential rights issue. Additionally,

Continued expansion to AroCell organization

In the continuing process of expanding the AroCell organization, Kiran Kumar Jagarlamudi, PhD has been hired as Product Specialist.Kiran Kumar Jagarlamudi received his initial Bachelor’s Degree in Veterinary Sciences from the College of Veterinary Sciences, Hyderabad, India. He became Master in Animal Science at the Swedish Agricultural University in Uppsala Sweden, and obtained the degree of PhD in Veterinary Medicine (Biochemistry) earlier this year at the Swedish Agricultural University. "Dr Kiran Kumar Jagarlamudi has an extensive research background in projects related to our

AroCell presents a robust TK1 blood-test at an international biomarker meeting

During the congress of the International Society of Oncology and Biomarkers (ISOBM), 3-7 October 2015 in Zakopane, Poland, AroCell presented its TK 210 ELISA blood test as a robust tool for researchers and clinicians. The test shows good sensitivity and performance in measuring TK1 protein in serum.Dr. Kiran Kumar Jagarlamudi and Professor Staffan Eriksson presented an abstract showing comparisons between TK1 protein levels in blood donors compared to TK1 levels in patients with different indications, measured with TK 210 ELISA. Patients with myelodysplastic syndrome (MDS, a pre-form of

Clarification regarding press release about CE marking

With reference to yesterday's press release, where we informed that we have filed TK 210 ELISA for CE mark registration at the Medical Products Agency (LMV), we would like to make a clarification. LMV does not approve products for CE mark but register the manufacturer and product as filed for CE marking. The product can then be marketed as CE marked. The processing time for this registration by LMV is usually 2-3 weeks. For additional information please contact:Jan Stålemark, CEO AroCell AB (publ) Tel: +46706-926206 info@arocell.com www.arocell.com About AroCell

AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA

AroCell has filed TK 210 ELISA for the CE-mark registration at the Swedish Medical Products Agency (Läkemedelsverket). The CE-mark registration is important for the on going clinical development program and an accepted diagnostic product.”This is a major milestone for AroCell” states Jan Stålemark, AroCell CEO. “As communicated earlier, we will continue the intensive efforts for clinical documentation for the product by supporting clinical studies. This is important in order to achieve full market acceptance”. “The ongoing process of establishing evidence-based clinical documentation for

There are no items matching the current filter
There are no more items matching the current filter
Back to top